AETHLON MEDICAL INC (AEMD)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
$1.69-6.63%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
Broken: Primary pillar broken — Reduce operating losses toward negative $1.5M or better: metric not reported.
Aethlon Medical aims to reduce losses and improve cash flow. Operating loss improved from negative $2.9M to negative $1.5M in 2026-Q2. Cash from operations also improved but remains negative near $1.75M. Analysts expect revenue to grow about 71% next year.
The company is still losing money with EPS far below zero. Operating losses and negative cash flow continue. The stock price dropped 76% from its high. Analysts expect EPS to remain negative for years.
The market prices in strong 71% revenue growth but expects continued losses. Our fair value is near $2.16, close to the current price.
Breaks if: cash from operations worsens beyond negative $1.75M in 2026-Q4
Continue efforts to manage and reduce operating losses and negative cash flow from operations.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity in the healthcare sector. The current thesis state is cautious, reflecting recent mixed performance and high risk factors.
The market seems to expect a durable premium for AEMD, but there is a significant expectations gap. This suggests that while the company has some premium valuation compared to peers, the fundamentals are not currently supporting that premium.
AEMD's fundamentals are likely to remain under pressure due to ongoing losses and mixed management execution. Recent efforts to advance clinical trials and manage expenses show some progress, but the overall financial performance has been below industry peers.
The long-term thesis hinges on the performance of sector bellwethers and the ability of AEMD to execute on its clinical and financial priorities. Any signs of recession or missed earnings from key industry players could negatively impact AEMD.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. Aethlon outlined a plan to complete oncology trial follow-up. This supports growth in their oncology segment. However, the latest earnings report showed a significant miss. This raises concerns about their financial performance and outlook.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: operating loss worsens beyond negative $1.5M in 2026-Q2
Continue efforts to manage and reduce operating losses and negative cash flow from operations.
Breaks if: revenue growth falls below 50% next year
In the next 1 to 3 years, AEMD's outlook will depend heavily on external market conditions and internal execution. Not investment advice.